Cancer Genetics Inc Recognized in Deloitte’s 2014 Technology Fast 500™ Awards
By Italia on November 14 2014
> CGI Recognized as One of North America’s Fastest Growing Companies Based on Revenue Growth. RUTHERFORD, N.J., November 14, 2014 (Globe Newsire) — Cancer Genetics, Inc. (Nasdaq: CGIX) (“CGI” or “the company”), an emerging leader in DNA-based cancer diagnostics, today announced it ranked 303 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing […]
Continue ReadingCancer Genetics Inc to Present at Cannacord Genuity Medical Technology & Diagnostics Conference
By Italia on November 13 2014
RUTHERFORD, N.J., November 13, 2014 (Globe Newswire) — Cancer Genetics, Inc., (Nasdaq: CGIX) an emerging leader in DNA-based cancer diagnostics, announced today that the company’s CEO, Panna Sharma, will present at the upcoming Canaccord Genuity Medical Technology & Diagnostics Conference. The event, which will be held at the Westin Grand Central in New York on Thursday, […]
Continue ReadingCancer Genetics Inc Receives Second Patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT®
By Italia on November 11 2014
Company receives second patent (US Patent No. 8,883,414) for FHACT® FHACT® has potential to improve cervical cancer detection for up to 2 million women in the US each year. RUTHERFORD, N.J., November 11, 2014 — Cancer Genetics Inc, an emerging leader in DNA-based cancer diagnostics, announced today that it has received a second US patent […]
Continue ReadingCancer Genetics Announces Strong Third Quarter With Growth Across All Categories
By Italia on November 10 2014
RUTHERFORD, N.J., November 10, 2014 (GLOBE NEWSWIRE) – Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014. Third quarter revenue of $3.22 million – overall revenue growth of ~90% over the same quarter of 2013, including 159% revenue growth in Biopharma […]
Continue Reading